{
  "trial_id": "NCT02802449",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "legally authorized representative would have been obtained prior to any study-related procedures being performed.",
      "label": "met"
    },
    {
      "criterion": "The subject will be assigned a screening number and will be contacted regarding eligibility once all screening procedures have been performed and laboratory results received.",
      "label": "unknown"
    },
    {
      "criterion": "medications, including prescription, herbal/vitamins, and all over-the-counter medications)",
      "label": "met"
    },
    {
      "criterion": "vital signs (sitting BP, heart rate), and a mini physical examination",
      "label": "met"
    },
    {
      "criterion": "Blood will be drawn (15 cc) for full biochemistry panel with glucose (mg/dl), complete blood count, HbA1c (%), calcium (mg/dl), phosphorus (mg/dl), albumin (mg/dl), pregnancy test and 25(OH)D (ng/ml) levels.",
      "label": "met"
    },
    {
      "criterion": "If eligible subjects will be given an appointment and preparatory instructions for Visit 2 (Baseline/Randomization/Dose#1).",
      "label": "unknown"
    },
    {
      "criterion": "VISIT 2 - BASELINE/ RANDOMIZATION/ STUDY DRUG DOSE#1 ADMINISTRATION.",
      "label": "unknown"
    },
    {
      "criterion": "If subject meets all of the inclusion criteria, they will be given an appointment and preparatory instructions for Study Visit 3.",
      "label": "unknown"
    },
    {
      "criterion": "VISIT 3 - STUDY DRUG DOSE#2 ADMINISTRATION (2 weeks after baseline).",
      "label": "unknown"
    },
    {
      "criterion": "Participant will be asked about any adverse events and changes in medications, including prescription, herbal, and over-the-counter medications.",
      "label": "met"
    },
    {
      "criterion": "Vital signs (sitting BP, heart rate) will be obtained.",
      "label": "met"
    },
    {
      "criterion": "Participant will be given their second dose of either two 50,000 IU tablets of oral Vitamin D3 or two tablets of Placebo to take under direct observation.",
      "label": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Poorly controlled high blood pressure (SBP \u2265160 mmHg or DBP \u2265 100 mmHg)",
      "label": "not_met"
    },
    {
      "criterion": "Poorly controlled diabetes (HbA1c >8.5%)",
      "label": "unknown"
    },
    {
      "criterion": "Screening Vitamin D (D2 and D3 level) < 5 or > 25 ng/ml",
      "label": "not_met"
    },
    {
      "criterion": "Estimated glomerular filtration rate (eGFR) < 45 ml/min",
      "label": "unknown"
    },
    {
      "criterion": "History of kidney stones (less than one year prior to screening)",
      "label": "not_met"
    },
    {
      "criterion": "History of drug, alcohol, or illicit substance abuse (within the past 6 months)",
      "label": "unknown"
    },
    {
      "criterion": "History of another chronic disease which the investigator feels should preclude the subject from entering the study",
      "label": "not_met"
    },
    {
      "criterion": "Liver function tests (LFTs) greater than twice the upper limit of normal",
      "label": "unknown"
    }
  ],
  "notes": "The patient has type 1 diabetes and cardiomyopathy, but is otherwise healthy. They have a family history of DM type 1 in their uncle and grandfather.",
  "_meta": {
    "topic_id": "65",
    "trial_id": "NCT02802449",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}